ãã€ãªå»è¬åäŒç€Ÿã§ãã XTL Biopharmaceuticals Ltd. ã¯ãèªå·±å
ç«çŸæ£ã®æ²»çã®ããã®å»è¬åã®ååŸãšéçºã«æºãã£ãŠããŸããå瀟ã®äž»ååè£è¬ã¯ãå
šèº«æ§ãšãªããããŒãã¹ããã³ã·ã§ãŒã°ã¬ã³çåçŸ€ã®æ²»çã®ããã®ãã§ãŒãº II æºåãæŽã£ãè³ç£ã§ãã hCDR1 ã§ããXTL Biopharmaceuticals Ltd. ã¯ãããŸããŸãªé©å¿çã«å¯Ÿãã hCDR1 ã®ç ç©¶ãéçºãããã³åååã«ã€ã㊠Yeda Research and Development Company Limited ãšã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããå瀟ã¯ä»¥å㯠Xenograft Technologies Ltd. ãšããŠç¥ãããŠããŸãããã1995 幎 7 æã« XTL Biopharmaceuticals Ltd. ã«ç€Ÿåã倿ŽããŸãããXTL Biopharmaceuticals Ltd. 㯠1993 幎ã«èšç«ãããã€ã¹ã©ãšã«ã®ã©ããã¬ã³ã«æ¬ç€Ÿã眮ããŠããŸãã